Skip to content

Internet Buzz (November 5, 2012) On Sarepta Therapeutics, Orphan Drug Eteplirsen, And Duchenne Muscular Dystrophy

November 6, 2012

       Internet buzz on Sarepta Therapeutics’ orphan drug Eteplirsen for the treatment of Duchenne Muscular Dystrophy (DMD) : 

**   1) November 5, 2012 article titled,”Sarepta Therapeutics Still Looks Ridiculously Undervalued”  

2)  Sarepta Therapeutics October 30, 2012 Press Release Announcing 3rd Q2012 Financial Results & Corporate Update for Wednesday, November 7, 2012  

3) November 2, 2012 article titled,” 3 Rising Mid or Small Cap Rare Disease Biotech Stocks: BioMarin Pharmaceutical, Synageva BioPharma, & Sarepta Therapeutics”  

4)  Action Duchenne 10th International Conference in London, November 9 – 10, 2012 with Dr. Ed Kaye (AVI BioPharma US/Sarepta Therapeutics) presenting results of the Phase 2B Eteplirsen 48-Week Extension Trial on Saturday, November 10, 2012  

5) November 1, 2012 article titled,” 3 Things to watch with Sarepta Therapeutics”  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: